InflaRx N.V.

NasdaqGS:IFRX Stock Report

Market Cap: US$147.8m

InflaRx Management

Management criteria checks 2/4

InflaRx's CEO is Niels Riedemann, appointed in Jan 2007, has a tenure of 17.92 years. directly owns 1.82% of the company’s shares, worth $2.68M. The average tenure of the management team and the board of directors is 4 years and 5.6 years respectively.

Key information

Niels Riedemann

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure17.9yrs
CEO ownership1.8%
Management average tenure4yrs
Board average tenure5.6yrs

Recent management updates

Recent updates

InflaRx (NASDAQ:IFRX) Will Have To Spend Its Cash Wisely

Jun 25
InflaRx (NASDAQ:IFRX) Will Have To Spend Its Cash Wisely

We're Keeping An Eye On InflaRx's (NASDAQ:IFRX) Cash Burn Rate

Dec 23
We're Keeping An Eye On InflaRx's (NASDAQ:IFRX) Cash Burn Rate

InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans

Aug 17
InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans

We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Rate

Mar 28
We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Rate

Can InflaRx (NASDAQ:IFRX) Afford To Invest In Growth?

Nov 30
Can InflaRx (NASDAQ:IFRX) Afford To Invest In Growth?

InflaRx seeks FDA emergency use nod for its treatment for critically ill COVID-19 patients

Sep 29

InflaRx reports Q2 results

Aug 05

InflaRx stock rises 13% on plans to file EUA for COVID drug in US for critically ill patients

Jul 26

Here's Why We're Watching InflaRx's (NASDAQ:IFRX) Cash Burn Situation

Jul 16
Here's Why We're Watching InflaRx's (NASDAQ:IFRX) Cash Burn Situation

InflaRx stock rises 14% as vilobelimab gets FDA fast track status for skin disorder

Jul 06

InflaRx granted FDA Type B meeting to discuss submissions for COVID therapy

Jun 29

Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?

Apr 01
Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?

Our First Look At InflaRx

Dec 29

Estimating The Fair Value Of InflaRx N.V. (NASDAQ:IFRX)

Dec 15
Estimating The Fair Value Of InflaRx N.V. (NASDAQ:IFRX)

InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans

Aug 27
InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans

InflaRx And Vilobelimab In AAV: Avoiding Clinical Hard Knocks

Aug 25

InflaRx initiates mid-stage vilobelimab skin cancer trial

Jun 08

We Think InflaRx (NASDAQ:IFRX) Can Afford To Drive Business Growth

May 01
We Think InflaRx (NASDAQ:IFRX) Can Afford To Drive Business Growth

Do Institutions Own InflaRx N.V. (NASDAQ:IFRX) Shares?

Mar 02
Do Institutions Own InflaRx N.V. (NASDAQ:IFRX) Shares?

We're Keeping An Eye On InflaRx's (NASDAQ:IFRX) Cash Burn Rate

Jan 08
We're Keeping An Eye On InflaRx's (NASDAQ:IFRX) Cash Burn Rate

InflaRx concludes enrollment in vilobelimab study in blood vessel inflammation disorder

Jan 05

InflaRx reports Q3 results

Oct 29

CEO

Niels Riedemann (51 yo)

17.9yrs

Tenure

Prof. Dr. Niels C. Riedemann, M.D. is Chief Executive Officer of InflaRx N.V. since 2007 and serves as its Executive Director. Dr. Riedemann founded InflaRx N.V. in 2007 as InflaRx GmbH. Dr. Riedemann spen...

Leadership Team

NamePositionTenureCompensationOwnership
Niels Riedemann
Co-Founder17.9yrsno data1.82%
$ 2.7m
Renfeng Guo
Co-Founder17.9yrsno data2.99%
$ 4.4m
Thomas Taapken
Chief Financial Officer4.2yrsno data0.0059%
$ 8.8k
Derval O'Carroll
Senior VP and Global Head of Regulatory Affairs & Compliance1.7yrsno datano data
Camilla Chong
Chief Medical Officer1.4yrsno datano data
Jan Medina
Head of Investor Relations & VPless than a yearno datano data
Christian Schmid
VP and Head of Legal Affairs & General Counselno datano datano data
Nicole Bertsch
Senior Director & Head of Human Resources3.8yrsno datano data
Maria Habel
VP, Head of Preclinical R&D and QC11.9yrsno datano data
Bruce Burnett
VP & Head of Medical Affairsno datano datano data
Kofi Boaten
Senior Director and Head of Supply Quality & Clinical Trial Suppliesno datano datano data
Peter Hurt
Senior Director and Head of Drug Safety & Pharmacovigilianceno datano datano data

4.0yrs

Average Tenure

56yo

Average Age

Experienced Management: IFRX's management team is considered experienced (4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Niels Riedemann
Co-Founderno datano data1.82%
$ 2.7m
Renfeng Guo
Co-Founderno datano data2.99%
$ 4.4m
Nicolas Fulpius
Independent Chairman of the Board17.9yrsno data0.79%
$ 1.2m
K. Reinhart
Member of Scientific Advisory Boardno datano datano data
P. Ward
Member of Scientific Advisory Boardno datano datano data
Richard Brudnick
Independent Non-Executive Director5.6yrsno data0.085%
$ 125.5k
Hege Hellstrom
Non-Executive Director1.7yrsno datano data
Mark Kubler
Independent Non-Executive Director9.9yrsno data1.63%
$ 2.4m
Anthony Gibney
Independent Non-Executive Director3.6yrsno data0.017%
$ 25.1k

5.6yrs

Average Tenure

53yo

Average Age

Experienced Board: IFRX's board of directors are considered experienced (5.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 00:50
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

InflaRx N.V. is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madhu KumarBaird
Mayur SomaiyaBMO Capital Markets Equity Research
Madhu KumarB. Riley Securities, Inc.